BFM
CRVS icon

Boothbay Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Boothbay Fund Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-48,211
Closed -$79K – 2320
2022
Q1 		$79K Hold
48,211
– – ﹤0.01% 2136
2021
Q4 		$116K Sell
48,211
-27,463
-36% -$107K ﹤0.01% 1681
2021
Q3 		$366K Buy
75,674
+64,474
+576% +$191K 0.01% 1232
2021
Q2 		$30K Hold
11,200
– – ﹤0.01% 1797
2021
Q1 		$34K Buy
+11,200
New +$40.5K ﹤0.01% 1493

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return